Barclays analyst Stephanie Davis yesterday morning initiated coverage of Waystar with an Overweight rating and $24 price target. Waystar is a leading provider of clearinghouse, patient payments, and revenue cycle technology, the analyst told investors in a research note. The firm believes the company’s profile will differentiate Waystar from its health tech peer group, meriting a premium multiple that is only partially reflected in the stock’s current valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
Questions or Comments about the article? Write to editor@tipranks.com